Parkinson’s drug shifts key biomarkers, trial results show
Phase 1 trial results showed an experimental oral therapy was associated with improved eye movement control, lower levels of neuroinflammatory biomarkers, and higher markers of nerve cell health in people with Parkinson’s disease . The results from the ARV-102-103 trial ( EUCT 2024-516888-84-00 ) bu
Source: Parkinson's News Today.